RNS news today13 Jan 2026 14:41
Innomed Tech Ltd.
Corporate and Debt Financing Update
Innomed Tech Ltd. (BC, Canada) (the “Company”) is pleased to announce that on January 8, 2026 the Company signed
a debt finance agreement with CIC Securitisation S.A. (Luxembourg). CIC Fund Securitisation S.A. previously provided
debt financing facility to the Company in the amount of €5,000,000 of which €4,600,000 was drawn down and together
with interest accrued, was redeemed and converted into equity in the Company in 2023.
CIC Fund Securitisation S.A. is providing an additional €5,500,000 unsecured five year debt financing facility through
Compartment Equity Trust Fund at 12.50% compound interest per annum, and paid on the earlier of the maturity date
or the date the debt notes are redeemed for equity in the Company at US$0.08 per common share with a full warrant
for each common share issued, exercisable at US$0.08, exercisable in part or whole on or before three years from the
date of issuance.
CIC Securitisation S.A. may elect to redeem the debt notes and any outstanding interest into equity in the Company
before the maturity date, subject to Canadian regulatory and TSX-V requirements. The debt finance transaction has
been structured to meet compliance with stock exchange policies, including no single investor holding more than 9.50%
of the issued and outstanding capital of the Company on a fully diluted basis upon the redemption of debt to shares and
warrants.
The finance will be subject to a 4.20% Luxembourg regulatory administrative fee payable over five (5) years in equal
instalments, on each 12-month anniversary following the first drawdown, on the total amount of the debt facility. In
addition, commissions to CIC Fund Securitisation S.A. of 4.50% of debt finance will be deducted from funds on each
drawdown.
The Company will also seek at the next General Meeting the approval of its shareholders to change the price of all
50,242,303 existing warrants to US$0.08 per warrant and extend the expiry date to December 31, 2029, subject to
regulatory and exchange approval.
The new debt facility, together with existing cash reserves, provides funds to significantly advance the development of
the PureFlow Catheter in both Europe and the US simultaneously. The EU patent has been awarded, affording patent
protection. Each approval, if successful, increases significantly the market distribution opportunity size and scope.
The development of the PureFlowCath Catheter System in Europe will be conducted through CIC Securitisation S.A.,
domiciled in Luxembourg / EU, together with European-based providers. This will also allow the Company to apply for
grant funding offered by various European bodies.
Contacts
Mr. Robert Rhodes – Chief Executive Officer
rrhodes@innomedtec.com
www.Innomedtec.com
Innomed Tech Ltd.
Mr. Billy Williams – Director
bwilliams@innomedtec.com
The Company’s first medical device devel
Sign In
Follow the stocks
